{
    "nctId": "NCT02133677",
    "briefTitle": "A Phase II Multi-center Pilot Study of Concurrent Temozolomide and Whole Brain Irradiation in Lung Cancer and Breast Cancer Patients With Brain Metastases",
    "officialTitle": "A Phase II, Open-label, Single-arm, Multi-center Pilot Study to Evaluate the Efficacy and Safety of Whole-brain Radiotherapy With Concomitant Temozolomide in Lung Cancer and Breast Cancer Patients With Brain Metastases",
    "overallStatus": "UNKNOWN",
    "conditions": "Lung Cancer and Breast Cancer Patients With Brain Metastases",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 24,
    "primaryOutcomeMeasure": "objective response rate (ORR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed lung cancer or breast cancer at primary site\n* Patient with inoperable brain metastases\n* Female or male, \u2265 20 and \\< 65 years of age\n* Karnofsky performance status (KPS) \u2265 70%\n* Life expectancy \u2265 12 weeks\n* Adequate organ function\n* Willing and able to provide a written informed consent\n\nExclusion Criteria:\n\n* Female of childbearing potential\\* who is pregnant/lactating or planning to be pregnant\n* Male whose partner is planning to be pregnant\n* Inability to swallow\n* Meningeal carcinomatosis\n* History of hypersensitivity to iodinated contrast media, temozolomide or any component of the study drugs\n* Prior use of temozolomide\n* Use of systemic chemotherapy within 2 weeks prior to the initiation of study treatment\n* Prior surgery, chemotherapy or radiotherapy for a brain neoplasm\n* Current use of valproic acid\n* Use of any investigational product within 4 weeks prior to the initiation of study treatment\n* Patient with any condition or disease which is considered not suitable for this study by investigator",
    "sex": "ALL",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}